Meridian · Women's Health After 50 · All modules in track

Key takeaways

• —Menopause is a retrospective clinical diagnosis: 12 months of amenorrhoea, no biochemistry needed over 45.
• —The late transition — not postmenopause — is when vasomotor symptoms and mood disturbance usually peak.
• —POI is not 'early menopause you can wait out'; untreated it carries excess CVD, osteoporosis and all-cause mortality risk.
• —Roughly a quarter of midlife 'menopause' presentations have a coexisting or alternative driver: hypothyroidism, iron deficiency, OSA, depression, or alcohol.

Graded claims

Supporting references

1. Executive summary of the Stages of Reproductive Aging Workshop +10 — Harlow et al., J Clin Endocrinol Metab 2012 https://pubmed.ncbi.nlm.nih.gov/22344196/
2. ESHRE Guideline: Premature Ovarian Insufficiency (2024 update) — ESHRE https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Premature-ovarian-insufficiency
3. Menopause: diagnosis and management (NG23) — NICE https://www.nice.org.uk/guidance/ng23

Key takeaways

• —Median total VMS duration in SWAN was 7.4 years; women whose symptoms begin in the early transition average over 11 years.
• —Estradiol withdrawal — not the absolute level — narrows the thermoneutral zone; this is why abrupt MHT cessation triggers rebound flushing.
• —KNDy neurons hypertrophy when oestrogen negative feedback is lost; NK3 antagonists (fezolinetant, elinzanetant) act on this circuit directly.
• —Persistent VMS correlates with worse endothelial function, greater carotid intima-media thickness and higher subclinical CVD burden — it may be a marker, not just a nuisance.

Graded claims

Supporting references

1. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN) — Avis et al., JAMA Intern Med 2015 https://pubmed.ncbi.nlm.nih.gov/25686030/
2. Fezolinetant for moderate-to-severe vasomotor symptoms (SKYLIGHT 2) — Johnson et al., J Clin Endocrinol Metab 2023 https://pubmed.ncbi.nlm.nih.gov/36734148/
3. Elinzanetant for vasomotor symptoms (OASIS 1 and 2) — Pinkerton et al., JAMA 2024 https://pubmed.ncbi.nlm.nih.gov/39172446/

Key takeaways

• —The CEE-alone arm (hysterectomised women) showed a non-significant reduction in breast cancer incidence — the opposite of the public perception.
• —Excess breast cancer with combined therapy is on the order of fewer than 1 extra case per 1000 women per year — comparable to two units of alcohol daily or obesity.
• —In women aged 50–59 starting therapy within 10 years of menopause, coronary and mortality signals are neutral to favourable.
• —WHI's average participant was 63 with a BMI of 28 — she is not the 52-year-old in your consulting room.
• —No increase in all-cause mortality was seen in either arm over 18 years of cumulative follow-up (Manson, JAMA 2017).

Graded claims

Supporting references

1. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality (WHI 18-year follow-up) — Manson et al., JAMA 2017 https://pubmed.ncbi.nlm.nih.gov/28898378/
2. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE) — Hodis et al., NEJM 2016 https://pubmed.ncbi.nlm.nih.gov/27028912/
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society — Menopause 2022 https://pubmed.ncbi.nlm.nih.gov/35797481/

Key takeaways

• —Transdermal estradiol avoids hepatic first pass: no increase in VTE risk, neutral triglycerides, safe with migraine with aura.
• —MHT is not contraception. The LNG-IUS provides both endometrial protection and contraception in one device.
• —Sequential regimens are for women still menstruating or within 12 months of their last period; continuous combined for those beyond it.
• —Micronised progesterone is the progestogen with the most favourable observational breast and cardiovascular profile, and is sedating — dose at night.
• —Unscheduled bleeding beyond 6 months on continuous combined therapy requires investigation, not a dose fiddle.

Graded claims

Supporting references

1. Menopause: diagnosis and management (NG23) — prescribing — NICE https://www.nice.org.uk/guidance/ng23
2. Hormone therapy and venous thromboembolism among postmenopausal women (ESTHER) — Canonico et al., Circulation 2007 https://pubmed.ncbi.nlm.nih.gov/17309934/
3. Global Consensus Position Statement on the Use of Testosterone Therapy for Women — Davis et al., 2019 https://pubmed.ncbi.nlm.nih.gov/31498871/

Key takeaways

• —NK3/NK1-NK3 antagonists are the first genuinely mechanism-targeted non-hormonal class, with effect sizes approaching but not matching oestrogen.
• —Paroxetine and fluoxetine are potent CYP2D6 inhibitors and reduce conversion of tamoxifen to endoxifen — use venlafaxine or citalopram instead.
• —CBT does not reduce flush frequency much but reliably reduces the bother and interference score — a legitimate outcome.
• —Placebo response in VMS trials runs at 30–50%, which is why uncontrolled testimonials for supplements are so persuasive and so unreliable.
• —Fezolinetant requires baseline and periodic liver function monitoring following post-marketing hepatic injury reports.

Graded claims

Supporting references

1. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society — Menopause 2023 https://pubmed.ncbi.nlm.nih.gov/37252752/
2. Efficacy and safety of fezolinetant (SKYLIGHT 1) — Lederman et al., Lancet 2023 https://pubmed.ncbi.nlm.nih.gov/36924778/
3. Cognitive behavioural therapy for menopausal symptoms (MENOS trials) — Ayers et al., Menopause 2012 https://pubmed.ncbi.nlm.nih.gov/22334056/

Key takeaways

• —Up to 80% of postmenopausal women have GSM; fewer than a quarter raise it unprompted, so you must ask.
• —Local oestrogen produces serum levels within the postmenopausal range and does not require a progestogen for endometrial protection.
• —Vaginal oestrogen reduces recurrent UTI recurrence substantially — a hard clinical endpoint, not a comfort measure.
• —Treatment is indefinite: symptoms return within weeks to months of stopping because the underlying atrophy returns.
• —Energy-based vaginal devices have not demonstrated benefit over sham in the better trials, and regulators have issued safety warnings.

Graded claims

Supporting references

1. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society — Menopause 2020 https://pubmed.ncbi.nlm.nih.gov/32852449/
2. A controlled trial of intravaginal estriol in postmenopausal women with recurrent UTI — Raz & Stamm, NEJM 1993 https://pubmed.ncbi.nlm.nih.gov/8350884/
3. FDA Safety Communication: Energy-based devices for vaginal 'rejuvenation' — FDA https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic

Key takeaways

• —Women lose roughly 2% of spinal BMD per year across the late transition and first postmenopausal years — around 10% in total.
• —WHI showed MHT reduced hip and vertebral fractures in an unselected population — the only therapy to do so in women not selected for osteoporosis.
• —FRAX does not capture falls risk, recent fracture recency, glucocorticoid dose or lumbar spine BMD — clinical judgement must override it.
• —Stopping denosumab without follow-on antiresorptive therapy causes rapid rebound bone loss and multiple vertebral fractures.
• —Progressive resistance plus impact training improves BMD modestly but improves falls risk and muscle function substantially.

Graded claims

Supporting references

1. Bone mineral density changes during the menopause transition (SWAN) — Greendale et al., J Bone Miner Res 2012 https://pubmed.ncbi.nlm.nih.gov/22006037/
2. Effects of Estrogen Plus Progestin on Risk of Fracture (WHI) — Cauley et al., JAMA 2003 https://pubmed.ncbi.nlm.nih.gov/14519709/
3. Discontinuation of denosumab and associated vertebral fracture risk — Cummings et al., J Bone Miner Res 2018 https://pubmed.ncbi.nlm.nih.gov/29105841/

Key takeaways

• —SWAN showed visceral fat rises sharply across the transition even when body weight is stable — waist measurement outperforms weight for tracking.
• —Age at menopause under 45 is an independent cardiovascular risk factor and belongs in the risk conversation.
• —Adverse pregnancy outcomes decades earlier are recognised risk enhancers in current prevention guidelines and are almost never recorded.
• —MHT is not indicated for cardiovascular prevention — but neither is it a cardiovascular contraindication in appropriately selected early postmenopausal women.
• —Statin under-prescription and under-titration in women is a persistent, measurable disparity.

Graded claims

Supporting references

1. Menopause Transition and Cardiovascular Disease Risk: AHA Scientific Statement — El Khoudary et al., Circulation 2020 https://pubmed.ncbi.nlm.nih.gov/33179545/
2. Adiposity changes across the menopause transition (SWAN) — Greendale et al., JCI Insight 2019 https://pubmed.ncbi.nlm.nih.gov/30843880/

Key takeaways

• —SWAN's cognitive substudy demonstrated a measurable but small decline in processing speed and verbal memory during the transition, with recovery in postmenopause.
• —The transition is a window of vulnerability for new and recurrent depression, especially with a prior history or PMDD.
• —Sleep disruption is often multifactorial: VMS awakenings, primary insomnia, restless legs and undiagnosed OSA, which rises sharply after menopause.
• —Oestrogen has evidence for depressive symptoms in the perimenopause but not in established postmenopausal major depression.
• —WHIMS: MHT initiated after 65 increased dementia incidence — prevention is not an indication at any age.

Graded claims

Supporting references

1. Longitudinal changes in cognition in the menopausal transition (SWAN) — Greendale et al., Neurology 2009 https://pubmed.ncbi.nlm.nih.gov/19487648/
2. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms — Gordon et al., JAMA Psychiatry 2018 https://pubmed.ncbi.nlm.nih.gov/29322164/
3. Conjugated Equine Estrogens and Incidence of Probable Dementia (WHIMS) — Shumaker et al., JAMA 2003 https://pubmed.ncbi.nlm.nih.gov/12771112/

Key takeaways

• —In SWAN, Black women reported the longest total VMS duration (over 10 years) and Chinese and Japanese women the shortest — and treatment access runs in the opposite direction to need.
• —There is no arbitrary stop date for MHT; continuation is a repeated shared decision, reviewed annually.
• —Documenting a natural-frequency risk discussion protects the patient's autonomy and the clinician equally.
• —Testosterone in women is licensed or supported only for hypoactive sexual desire disorder, at female physiological doses with level monitoring.
• —Most 'treatment failure' is under-dosing, wrong route, wrong progestogen, or an unaddressed second diagnosis.

Graded claims

Supporting references

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society — Menopause 2022 https://pubmed.ncbi.nlm.nih.gov/35797481/
2. Duration of menopausal vasomotor symptoms — racial/ethnic differences (SWAN) — Avis et al., JAMA Intern Med 2015 https://pubmed.ncbi.nlm.nih.gov/25686030/
3. Simple tools for understanding risks: from innumeracy to insight — Gigerenzer & Edwards, BMJ 2003 https://pubmed.ncbi.nlm.nih.gov/14512488/